SCHEMBL5035763

SCHEMBL5035763

NP(=O)(ON1CC1)ON1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615660 0.82 MMP1 (0.35)
SCHEMBL8763211 0.69
SCHEMBL43092 0.66 MMP1 (0.35)
SCHEMBL17479394 0.61 PARL (0.32)
SCHEMBL21145497 0.61 MMP1 (0.41)
SCHEMBL11338425 0.61 FDPS (0.33)
SCHEMBL8830223 0.59 FDPS (0.37)
SCHEMBL2165602 0.59 FDPS (0.37)
SCHEMBL4302310 0.57 MMP1 (0.38)
SCHEMBL5874245 0.57 FDPS (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213502-A1 Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms Pharmapotheca A, Inc. 2025-07-03 US claimed
US-20230321010-A1 Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms CHEMAPOTHECA, LLC (US) 2023-10-12 US claimed
US-11717498-B2 Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms Pharmapotheca A, Inc. (US) 2023-08-08 US claimed
US-20220162153-A1 Process for Making Levoamphetamine Pharmapotheca A, Inc. 2022-05-26 US claimed
US-11123310-B2 Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms PHARMAPOTHECA, LLC (US) 2021-09-21 US claimed
US-20210030699-A1 Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms PHARMAPOTHECA, LLC (US) 2021-02-04 US claimed
US-20200352883-A1 METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS CHEMAPOTHECA, LLC (US) 2020-11-12 US claimed
EP-3478363-A1 AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS Chemapotheca LLC (US) 2019-05-08 EP claimed
US-20180243241-A1 AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS CHEMAPOTHECA, LLC 2018-08-30 US claimed
WO-2017147375-A1 AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS CHEMAPOTHECA, LLC (US) 2017-08-31 WO claimed
WO-2015130660-A1 SYNTHESIS OF RACEMIC AMPHETAMINE DERIVATIVES BY CUPRATE ADDITION REACTION WITH AZIRIDINE PHOSPHORAMIDATE COMPOUNDS CHEMAPOTHECA, LLC (US) 2015-09-03 WO claimed
WO-2015130661-A1 SYNTHESIS OF CHIRAL AMPHETAMINE DERIVATIVES BY STEREOSPECIFIC, REGIOSELECTIVE CUPRATE ADDITION REACTION WITH AZIRIDINE PHOSPHORAMIDATE COMPOUNDS CHEMAPOTHECA, LLC (US) 2015-09-03 WO claimed
US-20150183716-A1 Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds CHEMAPOTHECA, LLC (US) 2015-07-02 US claimed
EP-4683622-A1 NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES Pharmapotheca A, Inc. (US) 2026-01-28 EP disclosed
US-12534428-B2 Non-distillative process for manufacturing high purity amphetamines Pharmapotheca A, Inc. (US) 2026-01-27 US disclosed
US-20250213502-A1 Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms Pharmapotheca A, Inc. 2025-07-03 US disclosed
US-20150183716-A1 Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds CHEMAPOTHECA, LLC (US) 2015-07-02 US disclosed
US-20150183716-A1 Synthesis of Chiral Amphetamine Derivatives by Stereospecific, Regioselective Cuprate Addition Reaction with Aziridine Phosphoramidate Compounds CHEMAPOTHECA, LLC (US) 2015-07-02 US disclosed
EP-1896040-A2 PHOSPHORAMIDATE ALKYLATOR PRODRUGS Threshold Pharmaceuticals, Inc. (US) 2008-03-12 EP disclosed
WO-2007002931-A2 PHOSPHORAMIDATE ALKYLATOR PRODRUGS THRESHOLD PHARMACEUTICALS, INC. (US) 2007-01-04 WO disclosed